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Memory T-cells, particularly, effector memory T cells are implicated in the pathogenesis 
of inflammatory diseases and may contribute to tissue injury and disease progression. 
Although erythema nodosum leprosum (ENL) is an inflammatory complication of lep-
rosy, the role of memory T cell subsets has never been studied in this patient group. 
The aim of this study was at investigate the kinetics of memory T cell subsets in patients 
with ENL before and after prednisolone treatment. A case–control study design was 
used to recruit 35 untreated patients with ENL and 25 non-reactional lepromatous 
leprosy (LL) patient controls at ALERT Hospital, Ethiopia. Venous blood samples 
were obtained before, during, and after treatment from each patient. Peripheral blood 
mononuclear cells (PBMCs) were isolated and used for immunophenotyping of T cell 
activation and memory T-cell subsets by flow cytometry. The kinetics of these immune 
cells in patients with ENL before and after treatment were compared with LL patient 
controls as well as within ENL cases at different time points. The median percentage of 
CD3+, CD4+, and CD8+ T-cells expressing activated T-cells were significantly higher in 
the PBMCs from patients with ENL than from LL patient controls before treatment. The 
median percentage of central and activated memory T-cells was significantly increased 
in patients with ENL compared to LL patient controls before treatment. Interestingly, 
patients with ENL had a lower percentage of naïve T cells (27.7%) compared to LL 
patient controls (59.5%) (P  <  0.0001) before treatment. However, after predniso-
lone treatment, patients with ENL had a higher median percentage of naïve T-cells 
(43.0%) than LL controls (33.0%) (P < 0.001). The median percentage of activated 
T-cells (effector memory and effector T-cells) was significantly increased in patients 
with ENL (59.2%) before treatment compared to after treatment with prednisolone 
(33.9%) (P < 0.005). This is the first work which has shown T-cell activation and the 
different subsets of memory T cells in untreated patients with ENL. Consequently, this 
study delineates the role of T-cell activation in the pathogenesis of ENL reaction and 
challenges the long-standing dogma of immune complex as a sole etiology of ENL 
reaction.
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inTrODUcTiOn
Leprosy is a disease caused by Mycobacterium leprae, an intracel-
lular acid-fast bacillus. It mainly infects the skin and peripheral 
nerves. Leprosy is a disease with a five-district forms called 
spectrum with the localized tuberculoid leprosy (TT) and the 
generalized lepromatous leprosy (LL) forming the two poles of 
the spectrum (1).
Leprosy reactions [reversal reactions and erythema nodosum 
leprosum (ENL)] are immune-mediated inflammatory compli-
cations of the disease which can occur before, during, or after 
successful completion of multidrug treatment (2). They cause a 
significant morbidity and nerve damage in leprosy patients (3). 
ENL is an inflammatory complication of leprosy, manifesting as 
tender erythematous skin lesions and systemic features of disease 
including fever, neuritis, and bone pain (4).
Immunological memory is a characteristic of adaptive immu-
nity. After infection, some antigen experienced T-cells generate 
memory T-cells which can provide life-long protection against 
the same infection. These memory T cells rapidly undergo clonal 
expansion to fight off the reoccurrence of the same infection (5). 
Memory is a signature of the acquired immune system. It results 
from antigen-specific lymphocytes clonal expansion and dif-
ferentiation, which eventually persist for a lifetime (6). Memory 
lymphocytes ensure immediate protection in peripheral tissues 
and provide recall responses to antigens in secondary lymphoid 
organs. In the cellular immune system, these functions are carried 
out by distinct cell types called effector and central memory T-cells 
(TCM cells). Protective memory is mediated by effector memory 
T-cells (TEM cells) that roam to inflamed peripheral tissues and 
confer immediate effector function, whereas reactive memory is 
carried out by TCM cells that home to T-cell areas of secondary 
lymphoid organs (7). TCM cells proliferate and differentiate to 
effector cells in response to antigenic stimulation (5).
Memory T-cells are characterized into two groups based on 
their phenotypic and functional profiles as TCM and TEM cells 
(7). The presence or absence of lymph node homing receptors 
CD62L (L-selectin) and C–C chemokine receptpr-7 (CCR7) 
on the cell surface are used to distinguish between TCM and 
TEM cells (8). CD62L or L-selection is a glycoprotein adhesion 
molecule which serves as a homing receptor for lymphocytes 
to enter secondary lymphoid tissues through high endothelial 
venules. CD62L shed from the surface during T-cell activation 
resulting in CD62L-negative effector cells (effector cells and TEM 
cells). Hence, effector memory T-lymphocytes do not express 
L-selectin, as they circulate in the periphery and have immedi-
ate effector functions upon encountering antigen. Unlike TEM 
cells, CD62L and CCR7 are present on the surface of TCM (7). 
Naïve (NTC) and TCM cells express CD62L and CCR7 for migra-
tion to secondary lymphoid organ. In the absence of CD62L 
and CCR7 molecules, TEM and effector T  cells (TEC) build up 
in the peripheral tissues. TEC cells are terminally differentiated 
memory T-cells. They are the relatively short-lived activated 
cells whose functions involve the interaction of an armed TEC 
cell with a target cell displaying specific antigen. They neither 
display memory marker (CD45RO) nor the homing receptor 
(CD62L) (7, 8).
Central memory T-cells produce IL-2, whereas TEM cells are 
characterized by increased secretion of effector cytokines such as 
IFN-γ and IL-4 (7). TCM cells are moderately long-lived memory 
cells, capable of differentiating into shorter-lived TEM cells upon 
antigen stimulation. In turn, TEM cells differentiate into TEC cells. 
TEC cells represent terminally differentiated TEM cells. Apoptotic 
death is the outcome of TEC cells upon increased proliferation 
and antigen exposure (9, 10). A NTC is a mature differentiated 
T-cell that has not encountered its cognate antigen within the 
periphery. NTCs are usually characterized by the surface expres-
sion of L-selectin (CD62L). They do not express memory markers 
(CD45RO) or activation markers such as CD25, CD44, and CD69. 
NTCs do not proliferate until they encounter their corresponding 
antigens. Stem memory T-cells have recently been described 
as sets of memory T-cells in mice and humans comprise 2–4% 
of CD4+ and CD8+ T-cells population in the periphery. It is 
speculated that these cells represent the earliest and long-lasting 
developmental stage of memory T-cells, displaying stem cell-like 
properties and expressing a gene profile between naïve and TCM 
cells (10).
Few studies have intended to identify the memory T  cell 
subsets in leprosy. One earlier study has shown that in fresh 
and unstimulated blood leukocytes from leprosy patients, 
memory T  cells predominated in the PB form of the disease 
and correlated with IFN-γ production but such result was not 
observed in MB patients (11). However, the study did not use 
an experimental design that allowed classification of memory 
T cell into subsets.
The correlation between TCM cell expression and pro-
inflammatory cytokine production with clinical presentation of 
multibacillary leprosy relapse case has been investigated (12). 
Increased frequency of TCM cells in relapsed patients was strongly 
correlated with the bacillary index and the number of skin lesions 
was reported by these authors. The study did not give attention to 
the memory subsets in leprosy spectrum rather they focused on 
relapse cases. Recently, a cross-sectional study of memory T-cells 
among type-1 reactions (T1R) has shown that circulating CD4+ 
TEM, CD8+ TEc, and pro-inflammatory cytokines increased at the 
onset of T1R in BL patients (13).
Memory T-cells have not been well characterized across lep-
rosy spectrum as well as in leprosy reactions particularly in ENL 
reactions. In the present study, for the first time we described 
memory-T cell subsets in LL and ENL reactions before and after 
prednisolone treatment.
MaTerials anD MeThODs
study Design
A case–control study with follow-up for 28  weeks was used to 
recruit 35 patients with ENL reaction and 25 non-reactional LL 
patient controls between December 2014 and January 2016 at 
ALERT Hospital, Ethiopia.
clinical case Definitions
The clinical assessment of the patient was used as main diagnostic 
criteria for ENL cases LL patient controls (4).
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Erythema Nodosum Leprosum
Erythema nodosum leprosum was clinically diagnosed when 
a patient had painful tender subcutaneous erythematous skin 
lesions with or without systemic features such as fever, neuritis, 
and bone pain occurring in patients with LL or borderline LL.
Lepromatous Leprosy
Lepromatous leprosy was clinically diagnosed when a patient had 
widely disseminated nodular lesions with ill-defined borders and 
BI above 2.
Acute ENL
Acute ENL was defined as an ENL episode lasting less than 
24 weeks of prednisolone treatment.
Chronic ENL
Chronic ENL was defined as an ENL occurring for 24 weeks or 
more during which a patient has required ENL treatment either 
continuously or where any treatment free period has been 27 days 
or less.
Recurrent ENL
Recurrent ENL was defined as a second or subsequent episode of 
ENL occurring 28 days or more after stopping or steady decrease 
of steroid treatment for ENL.
ENL Recurrence or Flare-up
Erythema nodosum leprosum recurrence or flare-up was defined 
as the appearance of new ENL nodules after initial control, either 
while on treatment or after 28 days off treatment.
New ENL Case
New ENL case was defined as the occurrence of ENL for the first 
time in a patient with LL.
Demographic and clinical Data collection
Structured questionnaire were used for clinical data recording 
for each participant. The ENL International STudy (ENLIST) 
format was modified and used for clinical data recording. The 
data collection sheet included the demographic, clinical, and 
diagnostic information set following the standard guideline at 
each time point. The clinical information included core points 
such as the clinical feature, skin lesion, nerve functions, and 
systemic involvement.
clinical sample collection
Blood samples were obtained from each patient three times: at 
recruitment before prednisolone administration and after 12 and 
24 weeks of prednisolone treatment foe ENL cases. The 12th week 
was chosen since the steady decrease in prednisolone after 12th 
week reaches less than half of the start dose and after 24th-week 
prednisolone administration normally off unless the patient 
experiences a chronic condition. The third time-point sample 
(24th week) was obtained when an ENL patient completed 
prednisolone treatment and the free treatment period is 15 days 
or more.
Peripheral Blood Mononuclear cell 
(PBMc) isolation, Freezing, and Thawing
Ten milliliters of venous blood was collected in sterile BD hepari-
nized vacutainer® tubes (BD, Franklin, Lakes, NJ, USA). PBMCs 
were separated by density gradient centrifugation at 800 × g for 
25 min on Ficoll-Hypaque (Histopaque, Sigma Aldrich, UK) as 
described earlier (14). Cells were washed three times in sterile 
phosphate-buffered saline solution (1× PBS, Sigma Aldrich®, 
UK) and resuspended with 1  ml of Roswell Park Memorial 
Institute [RPMI medium 1640 (1×) + GlutaMAX™ + Pen-Strip 
(GIBCO™, Life technologies™, UK)]. Cell viability was deter-
mined by 0.4% sterile Trypan Blue solution (Sigma Aldrich®, UK) 
ranged from 94 to 98%. PBMC freezing was performed using a 
freezing medium composed of 20% fetal bovine serum (FBS, heat 
inactivated, endotoxin tested ≤ 5 EU/ml, GIBCO® Life technolo-
gies, UK), 20% dimethyl sulfoxide in RPMI medium 1640 (1×). 
Cells were kept at 80°C for 48–72  h and transferred to liquid 
nitrogen. Thomson et al. method was used for cell thawing (15). 
The procedure is briefly described as: cells were removed from 
liquid nitrogen and taken to a water bath (preadjusted to 37°C) 
for 30 s until thawed half way and resuspended in 10% FBS in 
RPMI medium 1640 (1×) at 37°C containing 1/10,000 benzonase 
until completely thawed, washed two times (5  min each) and 
counted with trypan blue. A percentage viability of above 90% 
was obtained. Cell concentration was adjusted to 106 cells/ml in 
RPMI. Then, 1 ml/well cell suspension was pipetted on 24-well 
polystyrene cell culture plate (Corning® Costar® cell culture 
plates) and incubated at 37°C in a 5% carbon dioxide incubator. 
After an overnight resting, cells were brought to flow cytometry 
staining room for staining with fluorochromes conjugated anti-
bodies as described below.
surface staining for Flow cytometry
About 1 ×  106/ml cells’ suspension was transferred to round-
bottomed FACS tubes (Falcon®, BD, UK) followed by washing 
twice at 400 × g for 5 min at RT. Then, cells were resuspended 
in 50 µl of PBS and incubated in 1 ml of 10% human AB serum 
(Sigma Aldrich®, UK) for 10 min in the dark at room temperature 
to block non-specific Fc-mediated interactions and followed by 
centrifugation at 400 ×  g for 5  min. After resuspending cells 
in 50 µl PBS buffer, live/dead staining was performed at a con-
centration of 1 µl/1 ml live/dead stain (V500 Aqua, Invitrogen, 
Life technologies, UK) for 15 min at 4°C in the dark. Cells were 
washed once and stained for surface markers directed against 
anti-human CD3 (APC 450), anti-human CD4 (eFluoro780), 
anti-human CD8 (PerCp-Cy5.5), anti-human CD62L (APC), 
and anti-human CD45RO (PE), all from BD, Biosciences, UK. We 
used for each maker FMO, compensation controls, and unstained 
cells. Unstained cells were used to exclude the autofluorescence 
of cells. Cell viability was also checked before staining using 0.4% 
trypan blue.
sample acquisition and gating strategy
After the voltages on the photomultiplier tubes and compensa-
tion controls setting, the worksheet area was switched from 
the normal worksheet to the global worksheet. For inspection 
FigUre 1 | Gating memory T-cells on different cell types. (a) Gated on CD3+ T-cells, (B) gated on CD4+ T-cells, and (c) gated on CD8+ T-cells.
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purpose, the plots were produced on worksheet such as FSC-H 
versus FSC-A (to inspect the singlets), FSC-A versus viability 
marker (to inspect viable cells), and SSC-A versus FSC-A 
(to inspect populations such as lymphocytes, monocytes, granu-
locytes, etc.). The threshold for FSC was set to 5,000. For each 
sample, 500,000–1,000,000 cells were acquired.
Cells were gated into subpopulations with Flow Jo version 
10 (Tree Star, USA) by logicle (bi-exponential) method as 
recommended by Mohan et al. (16) and Ehlers (17). Activated 
and memory T-cells were defined as CD3+CD62L− and 
CD3+CD45RO+, respectively. Memory T-cells were further 
grouped into TCM cells (CD3+CD45RO+CD62L+) and activated 
memory T-cells (CD3+CD45RO+CD62L−). TEC and NTCs were 
defined as CD3+CD45RO−CD62L− and CD3+CD45RO−CD62L+, 
respectively (Figure 1). The relative percentage of each subpopu-
lation was copied to excel for each sample and finally an excel 
spreadsheet electronic data were generated and used for sub-
sequent statistical analysis.
statistical analysis
Differences in percentage of T-cell subsets were computed and 
statistically tested with two-tailed Mann–Whitney U test or 
Wilcoxon signed rank test for non-parametric distribution using 
STATA 14 ver. 2 (San Diego, CA, USA). Graphs were produced by 
GraphPad Prism version 5.01 for Windows (GraphPad Software, 
San Diego, CA, USA). Median and Hodges–Lehmann estimator 
were used for result presentation. Hodges–Lehmann is used to 
measure the effect size for non-parametric data (18). P-Value 
correction was applied for multiple comparisons. A statistical 
significance level of 0.05 was used to test the difference between 
cases and controls.
resUlTs
We described the median percentage of activated T-cells 
(CD62L−), total memory T-cells (CD45RO+), and the subgroups 
of memory T-cells before, during, and after treatment of ENL 
patients and compared the results with non-reactional LL patient 
controls as well as within ENL patients.
increased T-cell activation in Untreated 
enl Patients
The percentage of activated CD3+ T-cells (CD3+CD62L−) was 
significantly increased in untreated ENL patients (59.3%) in con-
trast to non-reactional LL patient controls (37.7%) (P < 0.0001; 
ΔHL = 22.4%). However, after treatment statistically a significant 
difference was not obtained between the groups. Similarly, the 
median percentage of activated CD4+ T-cells (CD4+CD62L−) 
was significantly higher (50.7%) in PBMCs of patients with ENL 
than in LL patient controls (27.1%) before treatment (P < 0.0001; 
ΔHL = 19.1%). However, a significant difference was not observed 
during and after treatment (P > 0.05). Nearly two-third of CD8+ 
T-cells (71.2%) was activated (CD8+CD62L−) in untreated ENL 
patients while it was only 45.4% in LL patient controls (P < 0.0001; 
ΔHL = 27.9%). On the other hand, after treatment, the frequency 
of activated CD8+ T-cells was significantly decreased to 34.5% 
in patients with ENL compared to 45.2% in LL patient controls 
(P ≤ 0.05; ΔHL = 10.1%) (Figure 2A).
When the trend of T-cell activation within ENL is compared 
before and after treatment, it was found that the median per-
centage of CD3+-activated T-cells before starting prednisolone 
treatment was higher (59.2%) than during treatment (47.0%) 
(P ≤ 0.05). After treatment, the median percentage of activated 
CD3+ T-cells was decreased to 33.9%, which was significantly 
lower than before treatment (P  <  0.0001; ΔHL  =  25.5%). 
Likewise, the median percentage of CD4+-activated T-cells was 
significantly higher (50.7%) before treatment than during treat-
ment (29.7%) (P < 0.0001; ΔHL = 17.75%). Similarly, the median 
percentage of activated CD8+ T-cells was significantly higher 
(71.2%) before treatment than during (59.5%) and after (34.5%) 
treatment (P ≤ 0.05) (Figure 2B).
FigUre 2 | Median percentage of total CD3+, CD4+, and CD8+ activated T-cells: (a) in patients with erythema nodosum leprosum (ENL) and lepromatous leprosy 
(LL) controls before, during, and after treatment, (B) within ENL patients before, during, and after treatment. *P ≤ 0.05; ***P < 0.001; ****P < 0.0001. Box and 
whiskers (a) and error bars (B) show median ± interquartile range.
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increased Total Memory T-cells in 
Untreated enl Patients
Erythema nodosum leprosum patients had significantly increased 
CD3+ total memory T-cell (CD3+CD45RO+) (40%) compared 
to LL patient’ controls (28%) before treatment (P  ≤  0.005; 
ΔHL = 10.5%). After treatment, the median percentage of CD3+ 
total memory T-cells in ENL patients and LL controls were 31.2 
and 32.7%, respectively, and the result was not statistically sig-
nificantly different (P > 0.05). Similarly, the median percentage 
of CD4+ total memory T-cells (CD4+ CD45RO+) was increased 
in untreated ENL patients (50%) compared to LL patient con-
trols (30.5%) (P < 0.0001; ΔHL = 20.3%). After treatment, the 
median percentage of CD4+ total memory T-cells in ENL patients 
(45.0%) was not significantly different compared to LL patient 
controls (41.8%) (P > 0.05). Interestingly, the median percentage 
of CD8+ memory T-cells (CD8+CD45RO+) was not statistically 
significantly different between the two groups before and after 
treatment (Figure 3A).
When the median percentage of total memory T-cells was 
compared within ENL patients before, during, and after treat-
ment, it was found that the median percentage of CD3+ total 
memory T-cells was significantly higher (41.1%) before treatment 
than during treatment (29.2%) (P ≤ 0.001; ΔHL = 11.2%) and 
after treatment (31.5%) (P ≤ 0.001; ΔHL = 9.8%). Similarly, the 
median percentage of CD4+ total memory T-cells was 52.3% 
before treatment and significantly decreased to 29.2% during 
treatment (P < 0.0001; ΔHL = 22.1%). On the other hand, unlike 
FigUre 3 | Median percentage of total CD3+, CD4+, and CD8+ memory T-cells: (a) in patients with erythema nodosum leprosum (ENL) and lepromatous leprosy 
(LL) controls before, during, and after treatment, (B) within ENL patients before, during, and after treatment. *P ≤ 0.05; **P < 0.005; ***P < 0.001; and 
****P < 0.0001. Box and whiskers (a) and error bars (B) show median ± interquartile range.
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CD3+ and CD4+ memory T-cells, the median percentage of CD8+ 
memory T-cells did not change within ENL patients before, dur-
ing, and after treatment (Figure 3B).
increased TeM cells in Patients with enl
Effector memory T-cells are memory T-cells which have lost their 
CD62L expression while migrating to the tissue and progressively 
gain functionality with further differentiation to TEC cells also 
called terminally differentiated T-cells (19). Measurement of 
TEM cells is the most commonly used method to determine the 
extent of T-cell activation in a disease state. We measured the 
proportion of TEC cells in unstimulated PBMCs from patients 
with ENL and LL controls before, during, and after treatment to 
prove our hypothesis that ENL is associated with increased T-cell 
activation.
The median percentage of CD3+ TEM cells (CD3+CD45RO+ 
CD62L−) in the PBMCs of patients with ENL was 26.6%, which 
was significantly higher than in LL patient controls (8.0%) 
before treatment (P <  0.0001; ΔHL =  18.3%). Conversely, the 
percentage of CD3+ TEM cell was found to be lower in patients 
with ENL (7.6%) than in LL patient controls (10.4%) after treat-
ment (P ≤ 0.05; ΔHL = 3.5%). Similarly, the median percentage 
FigUre 4 | Median percentage of CD3+, CD4+, and CD8+ effector memory T-cells: (a) in patients with erythema nodosum leprosum (ENL) and lepromatous leprosy 
(LL) controls before, during and after treatment, (B) within ENL patients before, during, and after treatment. *P ≤ 0.05; **P < 0.005; ***P < 0.001; ****P < 0.0001. 
Box and whiskers (a) and error bars (B) show median ± interquartile range.
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of CD4+ TEM cells (CD4+CD45RO+CD62L−) in the PBMCs of 
patients with ENL was nearly three times (24.6%) higher than 
in the PBMCs of LL patient controls (8.9%) before treatment 
(P < 0.0001; ΔHL = 18.4%). However, unlike CD3+ TEC cells, the 
median percentage of CD4+ TEC cells was not significantly different 
between the two groups after treatment (P > 0.05). Likewise the 
median percentage of CD8+ TEM cells (CD8+CD45RO+CD62L−) 
was significantly higher in patients with ENL (16.5%) than 
in LL patient controls (7.2%) before treatment (P  <  0.001; 
ΔHL = 6.7%). However, after treatment, the median percentage 
of CD8+ TEM cells in patients with ENL and LL controls did not 
show significant difference (Figure 4A).
Trend analysis has shown that TEM cells significantly 
decreased in ENL patients after prednisolone treatment. 
Untreated patients with ENL reactions had a higher CD3+ 
TEM cells (26.6%) than during treatment (16.8%) (P <  0.0001; 
ΔHL =  11.88%). The percentage of CD3+ T-cells expressing 
TEM cells (CD3+CD45RO+CD62L−) was considerably decreased 
to 7.6% after treatment, which was substantially lower than 
the median percentage of CD3+ TEM cells before treatment 
(P < 0.0001; ΔHL = 20.0%). Likewise, the median percentage 
of CD4+ TEM (CD4+CD45RO+CD62L−) cells was more than 
twofold higher (24.6%) before treatment compared to during 
treatment (11.4%) and the difference was statistically significant 
(P < 0.0001; ΔHL = 15.54%). The percentage of CD4+ TEM cells 
was remarkably reduced to 9.6% after treatment indicating the 
decreasing tendency of T-cell activation after prednisolone 
treatment of patients with ENL. About 16.5% of CD8+ T-cells 
FigUre 5 | Median percentage of CD3+, CD4+, and CD8+ central memory T-cells: (a) in patients with erythema nodosum leprosum (ENL) and lepromatous leprosy 
(LL) controls before, during, and after treatment, (B) within ENL patients before, during, and after treatment. *P ≤ 0.05; **P < 0.005; ***P < 0.001; ****P < 0.0001. 
Box and whiskers (A) and error bars (B) show median ± interquartile range.
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expressed TEM cells (CD8+CD45RO+CD62L−) before treatment. 
During treatment, the median percentage of CD8+ T-cells 
expressing TEM cells was notably decreased to 7.5%, which was 
significantly low compared to before treatment (P  ≤  0.005; 
ΔHL = 6.61%). However, unlike CD4+ and CD3+ TEM cells, the 
proportion of CD8+ TEM cells did not show significant change 
after treatment (6.5%) (Figure 4B).
TcM cells Play less role in enl reaction
The median percentages of CD3+ TCM (CD3+CD62L+CD45RO+) 
cells in patients with ENL and LL controls before, during, and 
after treatment were not statistically significantly different 
(P  >  0.05). Unlike CD3+ TCM, the proportion of CD4+ TCM 
(CD4+CD62L+CD45RO+) was significantly higher in patients 
with ENL (23.5%) than in LL patient controls (14.6%) before treat-
ment (P ≤ 0.005; ΔHL = 8.13%). However, the median percentage 
of CD4+ TCM cell was not significantly different between the two 
groups after treatment. Interestingly, the median percentage of 
CD8+ TCM (CD8+CD62L+CD45RO+) cell was significantly lower 
in patients with ENL (1.2%) than in LL patient controls (3.5%) 
before treatment (P ≤  0.0001; ΔHL =  2.3%). After treatment, 
the percentage of CD8+ TCM cell was slightly higher in patients 
with ENL (2.7%) than in LL patient controls (2.0%); however, the 
difference was not statistically significant (P > 0.05) (Figure 5A).
Comparison within ENL has shown that the percentage of TCM 
cells was not statistically significantly different before and after 
treatment (Figure 5B). This confirms that TCM cells do not play 
significant role in ENL reaction unlike TEM cells.
FigUre 6 | Median percentage of CD3+, CD4+, and CD8+ effector T-cells: (a) in patients with erythema nodosum leprosum (ENL) and lepromatous leprosy (LL) 
controls before, during, and after treatment, (B) within ENL patients before, during, and after treatment. *P ≤ 0.05; **P < 0.005; ***P < 0.001; ****P < 0.0001. Box 
and whiskers (a) and error bars (B) show median ± interquartile range.
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increased Tec cells in Untreated enl 
Patients
Effector memory T-cells (TEC) are short-lived unlike memory 
T-cells and they shortly undergo apoptosis once they meet their 
cognate antigens. Nearly one-third (29.3%) of CD3+ T-cells were 
effector cells (TEC) in the PBMCs of patients with ENL with the 
corresponding value of 20.0% in LL patient controls before treat-
ment and the difference was statistically significant (P ≤ 0.001; 
ΔHL = 9.0%). After treatment, the median percentage of CD3+ 
TEC cell was significantly decreased in patients with ENL (24.6%) 
compared to LL patient controls (35.3%) (P ≤ 0.05; ΔHL = 8.6%). 
With regard to the median percentage of CD4+ TEC cell, a statisti-
cally significant difference was not obtained between the two 
groups before, during, or after treatment. The median percentage 
of TEC cell expression in CD8+ T-cells in patients with ENL was 
62.7%, which was considerably higher than the value obtained 
for LL patient controls (39.5%) before treatment (P <  0.0001; 
ΔHL  =  25.8%). Similar to CD3+ TEC cell, the proportion of 
CD8+ TEC cell in patients with ENL was significantly decreased 
(38.9%) compared to LL patient controls (55.2%) after treatment 
(P ≤ 0.005; ΔHL = 14.4) (Figure 6A).
The median percentage of CD3+ TEC cells was lower before 
treatment (29.3%) than during treatment (43.4%) (P ≤  0.005). 
After treatment, the percentage of these cells decreased to 
24.6%. Similarly, the median percentage of CD4+ TEC cells was 
lower before treatment (14.0%) than during treatment (22.9%) 
(P ≤ 0.05). After treatment, the percentage of CD4+ TEC cells was 
decreased by half (12.1%) than during treatment (P ≤ 0.05). Like 
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CD3+ TEC cells, the percentage of CD4+ TEC cells did not show sig-
nificant difference before and after treatment. On the other hand, 
the median percentage of CD8+ TEC cells was higher (62.7%) 
before treatment than during treatment (53.4%) (P ≤ 0.05). After 
treatment, the percentage of CD8+ TEC cells was considerably 
decreased to 38.9% compared to during treatment (P ≤ 0.05) and 
before treatment (P < 0.0001) (Figure 6B).
nTcs Decreased in enl Patients compared 
to non-reactional ll controls
Despite the higher bacterial load in patients with LL patients, 
the median percentage of CD3+ NTCs was significantly higher 
(59.5%) in these patients compared to that in patients with ENL 
(27.7%) before treatment (P <  0.0001; ΔHL =  26.5%). During 
treatment, the median percentage of CD3+ NTCs significantly 
decreased to 32.9% in LL patient controls while in patients 
with ENL the percentage was slightly increased to 31.8%. After 
treatment, the percentage of CD3+ NTCs was further increased 
to 42.9% in patients with ENL but did not change in LL patient 
controls (33.0%), and the difference between the two groups was 
statistically significant. Similarly, the median percentage of CD4+ 
NTCs in patients with ENL (34.0%) was significantly lower than 
that in LL patient controls (61.5%) before treatment (P < 0.0001; 
ΔHL = 25.6%). However, during and after treatment the median 
percentage of CD4+ NTCs did not show statistically significant 
difference (P > 0.05). On the other hand, the median percentage 
of CD8+ NTCs in patients with ENL was more than three times 
lower (15.4%) than in LL patient controls (50.5%) before treat-
ment (P < 0.0001; ΔHL = 31.6%). During treatment, while the 
median percentage of CD8+ NTCs increased to 35.5% in patients 
with ENL, it was decreased to 38% in LL patient controls. After 
treatment, the median percentage of CD8+ NTCs in patients with 
ENL and LL controls was 51.5 and 32.8%, respectively, and the 
difference between the two groups was statistically significant 
(P ≤ 0.05; ΔHL = 14.4%) (Figure 7A).
Comparison within ENL has shown that the percentage of 
CD3+ TNC cell was lower (27.7%) before than after treatment 
(42.9%) (P <  0.0001). Similarly, the percentage of CD4+ TNC 
cells was lower (34.1%) before treatment than after treatment 
(40.4%) (P ≤ 0.005). The percentage of CD8+ TNC cells was 15.4% 
before treatment but increased to 51.5% after treatment and it 
was significantly higher than before treatment (P  <  0.0001) 
(Figure 7B).
Decreased regulatory T-cells (Treg)/TeM 
cells ratio in enl Patients compared to 
ll controls
The median percentage ratio of Treg (CD3+CD4+CD25+FoxP3+) 
to TEM (Treg/TEM cells) was significantly lower in untreated patients 
with ENL (0.077) than in LL controls (0.44) before treatment 
(P ≤  0.0001). However, after treatment the median percentage 
ratio of Treg/TEM cells was significantly increased in patients 
with ENL (0.522) compared LL controls (0.255) (P  ≤  0.005) 
(Figure 8A).
When the ratio of Treg/TEM cells is compared within ENL 
groups, it was found that patients with ENL had a significantly 
lower median percentage of Treg/TEM cells (0.077) before treatment 
than after treatment (0.552) (P < 0.0001) (Figure 8B).
DiscUssiOn
The ability of inflammatory cells to respond to pathogens is crucial 
for maintaining healthy conditions. In mammals, lymphocytes 
leave the circulation and migrate to secondary lymphoid organs, 
such as lymph nodes, where antigens are presented. When an 
antigen is encountered, directed release of immune cells to sites 
of inflammation orchestrates host defense. Both constitutive and 
inflammatory leukocyte trafficking is controlled by adhesion 
molecules. The initial tethering of leukocytes to the endothelium 
and to other leukocytes is assisted by selectins, particularly by 
L-selectins. L-selectin directs neutrophils and lymphocytes to 
sites of inflammation. Upon T-cell activation L-selectin is shed 
from the leukocyte surface (8, 20).
In this study, the status of T-cell activation and the different 
subtypes of memory T-cells were investigated. In leprosy, the 
different classes of memory T-cells have not been studied. To 
our knowledge, it is for the first time that the different subtypes 
of memory T-cells and T-cell activation are phenotypically 
described in patients with ENL and LL. We are the first to study 
the status of T-cell activation in patients with ENL. Not only 
T-cell activation and the different classes of memory T-cells are 
described but also the changes of these immune cells over time 
before, during, and after prednisolone treatment were investi-
gated. Therefore, our present data will provide basic information 
for future studies involving T-cell activation and memory T-cells 
in ENL.
increased activation of T-cells in 
entreated enl
In our study, patients with ENL had significantly higher percent-
age of CD3+, CD4+, and CD8+ activated T-cells than LL patient 
controls before treatment. However, after prednisolone treat-
ment, T-cell activation was not significantly different in patients 
with ENL and LL controls except for the transient activation of 
CD8+ T-cells. This result is the evidence of T-cell activation in 
patients with ENL reactions. In vitro stimulation of PBMCs from 
patients with ENL reaction with M. leprae whole-cell sonicate 
has shown an increased T-cell response as assessed by IFN-γ and 
TNF-α production (data not shown). Excessive T-cell activation 
as a cause of tissue damage in several inflammatory diseases has 
been described in many studies (21, 22). The finding of T-cell 
activation in patients with ENL implies the involvement of T-cell 
activation in the pathogenesis of ENL.
In this study, changes in the percentage of activated T-cells 
were investigated before, during, and after prednisolone treat-
ment within ENL groups. The percentages of CD3+, CD4+, 
and CD8+ activated T-cells were significantly reduced during 
and after prednisolone treatment. The reduction of activated 
T-cells following prednisolone treatment may be explained by 
the immunosuppressive activity of prednisolone. Although 
studies showing the effect of prednisolone treatment on T-cell 
response in leprosy reactions is lacking, several studies in other 
FigUre 7 | Median percentage of CD3+, CD4+, and CD8+ naïve T-cells: (a) in patients with erythema nodosum leprosum (ENL) and lepromatous leprosy (LL) 
controls before, during, and after treatment, (B) within ENL patients before, during, and after treatment. *P ≤ 0.05; **P < 0.005; ***P < 0.001; ****P < 0.0001. Box 
and whiskers (a) and error bars (B) show median ± interquartile range.
11
Negera et al. Memory T-Cells in ENL Reactions
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1149
inflammatory diseases have shown the suppressive effect of 
prednisolone on the T-cell response (23–25). Consequently, our 
present findings provide evidence that the effect of prednisolone 
treatment of patients with ENL could be through suppressing 
T-cell responses.
TeM cells significantly increased in 
Untreated enl Patients
The median percentage of CD3+, CD4+, and CD8+ T-cells 
expressing TEM cells in the PBMCs of patients with ENL was sig-
nificantly high compared to LL patient controls before treatment. 
Such a difference was not observed after prednisolone treatment 
of patients with ENL. This implies that in patients with ENL, 
there is a continuous activation of T-cells. This continuous T-cell 
activation could lead to an excess antibody–antigen complex 
formation but insufficient to clear bacilli from lesions (26). This 
means the rate of immune-complex formation is greater than the 
rate of immune-complex clearance, which leads to further tissue 
damage through recruitment of inflammatory molecules to the 
site of immune-complex deposition. In LL, there is high load of 
bacilli. The macrophages are laden with this intact bacillus but 
unable to process and present to T-cells for further action. LL 
patients are also characterized by the presence of high antibody 
titer although these antibodies play little or no role to protect 
the multiplication of M. leprae in these patients. Spontaneous 
FigUre 8 | The median percentage of regulatory T-cells (Treg)/effector memory T-cells (TEM) cells: (a) in patients with erythema nodosum leprosum (ENL) and 
lepromatous leprosy (LL) controls before, during, and after treatment, (B) within ENL patients before, during, and after treatment. **P < 0.005; ***P < 0.001; 
****P < 0.0001.
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activation of T-cells could lead to the macrophage activation or 
B-cell activation or both. Macrophage activation results in the 
processing of the bacilli and releasing the processed bacterial 
components, which further activate other immune cells. The 
activation of B-cells by T-cells could produce functional antibod-
ies, which form immune-complex with the already accumulated 
bacterial antigens. However, this scenario is less likely to happen 
as it is confirmed that the different subtypes of B-cells did not 
significantly different in ENL and LL patients (data not shown). 
Whichever the activation takes place, if excess immune-complex 
is formed due to the presence of excess antigens in the body, 
it leads to more immune-complex formation than immune-
complex clearance, and hence, some immune-complexes deposit 
in tissues and often induce inflammatory responses and can cause 
tissue damage. The causes of tissue damage could be due to the 
action of complement cleavages, which induces the release of 
tissue damaging granules such as histamine or the recruitment 
of inflammatory cells such as neutrophils and macrophages into 
the tissue. However, this assumption needs further study to give 
definitive evidence. Previous studies have suggested that human 
TEM cells display characteristic sets of chemokine receptors and 
adhesion molecules that are required for homing to inflamed tis-
sues and they have an immediate effector function (20, 27). This 
situation could amplify the immune response and hence further 
aggravate tissue damage in a vicious circle (Figure 9).
A kinetic analysis of the percentage of TEM cells in the PBMCs 
from patients with ENL before, during, and after prednisolone 
treatment showed that the median percentage of TEM cells was 
decreased from 27% before treatment to 8% after treatment with 
an effect size of 20%. It has been described in previous sections 
that TEM cells rapidly differentiate to TEC cells upon antigenic 
stimulation. The consequence of excessive expression of TEM 
cells is detrimental to tissue damage (9). In apparently healthy 
individuals, TEC cells do not express CD62L or CCR7 and hence 
do not home to lymph nodes (10). A breakdown in the compart-
mentalization of such TEC cells is predicted to have unfavorable 
consequences for the immune system. Hence, the finding of an 
increased percentage of TEM cells in patients with ENL before 
treatment suggests that TEC cells take part in the process of tissue 
damage observed in these patients.
More T-cells in enl Patients are antigen 
experienced than in ll Patients
Interestingly, the median percentage of NTCs’ expression in CD3+, 
CD4+, and CD8+ T-cells in the PBMCs of patients with ENL 
was significantly low compared to LL controls before treatment 
implying that T-cells from patients with ENL have more antigenic 
exposure than those from LL. It is important to note that patients 
with ENL had LL before they developed ENL during which a 
high percentage of NTCs is expected since higher percentage of 
NTCs was investigated in this study in LL patients. Following the 
development of ENL, the percentage of NTCs drops to below 30%. 
This implies that either those previously NTCs became responsive 
and able to recognize their cognate antigen or the newly produced 
T-lymphocytes during the onset of ENL reactions are able to 
recognize and respond to the existing M. leprae antigens unlike 
in LL. It is an established fact that despite the high bacterial load 
in patients with LL, the cell-mediated immune response is virtu-
ally absent (28, 29). In addition to a specific loss of cell-mediated 
immune response against M. leprae in these patients, a relative 
impairment of the ability of lymphocytes to react in vitro has also 
been reported. Furthermore, lymph nodes from patients with LL 
show a deficiency of these cells in those areas associated with the 
development of cell-mediated immune responses (14, 28–31). 
Therefore, the significantly reduced median percentage of NTCs 
in blood from patients with ENL reaction provides an evidence 
of T-cell responsiveness in patients with ENL. This means that 
unlike in LL patients, the NTCs in ENL patients are primed in 
recognition of the M. leprae antigen (Figure 9).
The median percentage of NTCs was significantly increased 
after prednisolone treatment within ENL groups. The percentage 
of NTCs in untreated patients with ENL reactions was less than 
30% and was increased to nearly 50% after treatment. Previous 
studies have shown that prednisolone treatment increases in a 
dose-dependent manner the percentage of NTCs in experimental 
FigUre 9 | Illustration of the possible immunopathogenesis of erythema nodosum leprosum (ENL) based on the present findings. Based on the finding of this study, 
the immunopathogenesis of ENL can be illustrated using the following key steps: (1) spontaneous activation of T-cells leading to activation of macrophages that are 
already loaded with intact Mycobacterium leprae. Then, the activation of macrophages produces three key events: processing M. leprae and releasing of the 
processed antigens; antigen presentation to Th1 and production of pro-inflammatory cytokines such as IFN-γ and TNF-α and other inflammatory molecules. The 
causes of spontaneous T-cell activation should be investigated in the future. (2) Antigen presentation to Th1 stimulates Th1 to produce chemokines, which recruits 
macrophages to the site of antigen deposition, pro-inflammatory cytokines (IFN-γ, TNF-α), and other inflammatory mediators that increase expression of vascular 
adhesion molecules. (3) The processed and released antigens bind to the presynthesized antibody leading to antigen–antibody complex formation, which in turn 
recruits C1q complement and hence immune-complex formation. Following the immune-complex formation, neutrophils will be recruited to the site of immune-
complexes. (4) Once immune-complex is formed, it amplifies the immune response which leads to aggressive antigen presentation, immunoglobulin synthesis, and 
activation of other inflammatory T-cells. (5) The pro-inflammatory cytokines and other inflammatory molecules released from macrophages, Th17, and Th1 and the 
immune-complex formation beyond clearance lead to tissue damage as sketched above.
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mice. Hence, the finding of high percentages of NTCs after pred-
nisolone treatment of patients with ENL may be explained by the 
fact that prednisolone resolves inflammation at least partly by 
increasing the percentage of NTCs which concurrently reduce the 
percentage of activated T-cells.
In our present work, we have shown that ENL reaction is 
associated with increased T-cell activation. Our findings suggest 
that ENL reaction is a T-cell-mediated pathology. Hence, the 
T-cell-mediated pathology of ENL will provide further insights 
into disease mechanisms and will potentially result in promising 
new therapeutic options. Therefore, future ENL studies should 
consider these fertile areas to improve the treatment and manage-
ment of ENL. It might also be important to think of to interfere 
with T-cell trafficking into tissues and thereby reducing inflam-
mation in these patients.
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